Phase II
Two of the biggest drugmakers in the HIV space are teaming up on a combination therapy that has the potential to be a game-changer for patients diagnosed with the dangerous virus for which there is no known cure.
Many drugs for Alzheimer’s disease have demonstrated promise in early and mid-stage clinical trials, but then go on to fail in larger late-stage trials. It’s too early to know if that will be the case with Eli Lilly’s donanemab, but it showed unusually good primary results in a Phase II trial, with decidedly mixed secondary endpoint results.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
The European Medicines Agency has launched a safety review of bluebird bio’s thalassaemia drug Zynteglo, a conditionally licensed gene therapy in Europe.
While existing vaccines are being rolled out worldwide, Novavax’s is demonstrating effectiveness in late-stage trials and the partnership of Sanofi and Translate Bio is beginning early-stage trials for their mRNA vaccine.
Patients in a Phase II trial have begun receiving Moderna’s vaccine against the SARS-CoV-2 variant first identified in South Africa, the company announced.
Preliminary findings of LentiGlobin suggested that the BB305 LVV vector was present in the AML blast cells, but there was not sufficient information to determine causality.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
AnaptysBio started the week with some disappointing news for its lead antibody drug imsidolimab.
Merck and Ridgeback Biotherapeutics announced preliminary results from Ridgeback’s Phase IIa trial of molnupiravir in COVID-19.
PRESS RELEASES